Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

被引：0
|
作者：
Motzer, Robert J.
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Bourlon, Maria T.
Shah, Amishi Yogesh
Porta, Camillo
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Rangwala, Fatima A.
Askelson, Margarita
Panzica, Julie
Fedorov, Viktor
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Gustave Roussy, Villejuif, France
[3] Bradford Hill Clin Res Ctr, Santiago, Chile
[4] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] Univ Bari Aldo Moro, Bari, Italy
[9] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[10] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[11] Oncoclin Grp, Porto Alegre, Brazil
[12] Fdn Richardet Longo, Inst Oncol Cordoba, Cordoba, Argentina
[13] Westmead Hosp, Westmead, NSW, Australia
[14] Macquarie Univ, Westmead, NSW, Australia
[15] Westmead Hosp, Sydney, NSW, Australia
[16] Macquarie Univ, Sydney, NSW, Australia
[17] Univ Colorado, Sch Med, Aurora, CO USA
[18] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[19] Eva Mayr Stihl Canc Ctr, Klinikum Stuttgart, Stuttgart, Germany
[20] Exelixis Inc, Alameda, CA USA
[21] Bristol Myers Squibb, Princeton, NJ USA
[22] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[23] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
  • [22] TEMPORAL TRENDS IN GRADE 3/4 ADVERSE EVENTS AND ASSOCIATED COSTS OF NIVOLUMAB PLUS CABOZANTINIB (N plus C) VERSUS SUNITINIB (S) FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC)
    Geynisman, D.
    McGregor, B.
    Burotto, M.
    Porta, C.
    Suarez, C.
    Bourlon, M. T.
    Stwalley, B.
    Du, E. X.
    Gu, C.
    Yang, X.
    Betts, K. A.
    Huo, S.
    Choueiri, T. K.
    VALUE IN HEALTH, 2021, 24 : S36 - S36
  • [23] A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
    Choueiri, Toni K.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Aren, Osvaldo Rudy
    Shah, Amishi
    Kessler, Elizabeth Riley
    Hsieh, James J.
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
    Powles, Thomas
    Choueiri, Toni K.
    Burotto, Mauricio
    Escudier, Bernard
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Hamzaj, Alketa
    Porta, Camillo
    Hocking, Christopher
    Kessler, Elizabeth R.
    Gurney, Howard
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Apolo, Andrea B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [25] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
    Tomita, Yoshihiko
    Kondo, Tsunenori
    Kimura, Go
    Inoue, Takamitsu
    Wakumoto, Yoshiaki
    Yao, Masahiro
    Sugiyama, Takayuki
    Oya, Mototsugu
    Fujii, Yasuhisa
    Obara, Wataru
    Motzer, Robert J.
    Uemura, Hirotsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (01) : 12 - 19
  • [27] Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N plus I) or sunitinib (SUN) in the CheckMate 214 trial.
    Carril-Ajuria, Lucia
    Motzer, Robert J.
    Tannir, Nizar M.
    McDermott, David F.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Donskov, Frede
    Rini, Brian I.
    Jiang, Ruiyun
    Lee, Chung-Wei
    Desilva, Heshani
    Albiges, Laurence
    Roussy, Gustave
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
    Albiges, Laurence
    Motzer, Robert J.
    Trevino, Sergio
    Kanesvaran, Ravindran
    Centkowski, Piotr
    Reimers, Melissa A.
    Sade, Juan Pablo
    Pouessel, Damien
    Biscaldi, Elisa
    Esteban, Emilio
    Arranz Arija, Jose Angel
    Tykodi, Scott S.
    Ma, Haijun
    Zhou, Lei
    Van Kooten Losio, Maximiliano A. G.
    Simmons, Andrew
    Rangwala, Fatima A.
    Braun, David A.
    Choueiri, Toni K.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [29] Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)
    Mantia, Charlene
    Jegede, Opeyemi
    Viray, Hollis
    Atkins, Michael B.
    Rosenblatt, Lisa
    Yin, Xin
    McDermott, David F.
    Regan, Meredith M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Plimack, E. R.
    Porta, C. G.
    George, S.
    Powles, T. B.
    Donskov, F.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M-O.
    Tomita, Y.
    Rini, B. I.
    McHenry, M. B.
    Lee, C-W.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
12345